Proteasome inhibition in hematologic malignancies

Annals of Medicine
Paul G RichardsonKenneth C Anderson

Abstract

Hematologic malignancies, including multiple myeloma (MM), will account for more than 100,000 new cases of cancer and over 57,000 deaths in the United States in 2003. Treatment of MM is a serious challenge, because despite a variety of available therapies, median survival is short. A new therapeutic area focuses on inhibiting the activity of the proteasome, a 26S protease complex involved in cell cycle regulation, cell adhesion, inflammation, and protein turnover. The novel proteasome inhibitor, bortezomib (Velcade), was recently approved for use in patients with refractory and relapsed MM and to date is the only proteasome inhibitor to have entered clinical trials. Bortezomib has demonstrated activity with manageable toxicity in a variety of hematologic malignancies in addition to MM, including leukemia and non-Hodgkin's lymphoma. This article reviews clinical information on bortezomib in hematologic malignancies both as monotherapy and in combination with dexamethasone. Preliminary reports of bortezomib in combination with Doxil (pegylated liposomal doxorubicin), melphalan, and thalidomide are discussed, and current trials are described. Available data suggest that bortezomib will be useful in the treatment of a variety of he...Continue Reading

References

Aug 7, 2001·Seminars in Hematology·K C Anderson
Nov 17, 2001·American Journal of Clinical Pathology·P J Elliott, J S Ross
Dec 12, 2001·Seminars in Oncology·J Adams
Mar 2, 2002·The Journal of Biological Chemistry·Teru HideshimaKenneth C Anderson
Apr 18, 2002·Leukemia·J B Almond, G M Cohen
Aug 14, 2002·Mayo Clinic Proceedings·S Vincent RajkumarUNKNOWN Mayo Clinic Myeloma, Amyloid, and Dysproteinemia Group
Oct 23, 2002·Proceedings of the National Academy of Sciences of the United States of America·Nicholas MitsiadesKenneth C Anderson
Nov 15, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiSteven L Soignet
Feb 6, 2003·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Sep 13, 2003·Blood·Bart BarlogieJohn Crowley

❮ Previous
Next ❯

Citations

Oct 29, 2009·Blood·A Keith StewartJesus F San-Miguel
May 1, 2010·Cancer Cell International·Marie-Josée FournierRachid Mazroui
Oct 2, 2009·Haematologica·Eric W SchaeferUNKNOWN Mayo P2C Phase II Consortium
Dec 5, 2009·Advances in Hematology·Adele BologneseBruno Rotoli
Jan 26, 2012·Expert Review of Hematology·Mahmoud R GaballaPaul G Richardson
Jul 28, 2010·Biochimica Et Biophysica Acta·Roberta R Ruela-de-SousaGwenny M Fuhler
Nov 14, 2008·Cancer Letters·Angela IanaroArmando Ialenti
Jul 6, 2007·BioFactors·Chae Hyeong LeeYong-Sang Song
Sep 13, 2006·International Journal of Experimental Pathology·Roman SafránekMilan Holecek
Sep 8, 2006·Biochemical Pharmacology·Francesco Pacifico, Antonio Leonardi
May 12, 2005·Blood Reviews·Daniel V T Catenacci, Gary J Schiller
Jul 23, 2016·Expert Review of Hematology·Rebecca CitrinDavid T Teachey
Jun 30, 2005·The Annals of Pharmacotherapy·Pascal AndréJean-Eudes Fontan
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Melanie B Thomas, James L Abbruzzese
Nov 18, 2005·Cancer Chemotherapy and Pharmacology·Terzah M HortonStacey L Berg
Mar 4, 2017·Scientific Reports·Yock Ping ChowVyomesh Patel
Apr 1, 2006·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Luca Paoluzzi, Owen A O'Connor
Mar 11, 2005·Expert Review of Anti-infective Therapy·Patricia P Klinger, Ulrich Schubert
Mar 8, 2008·Hematological Oncology·Scott Marshall McCloskeyAlexandra E Irvine
Feb 18, 2006·Cell Death and Differentiation·H J KimA S Baldwin
Apr 9, 2019·British Journal of Haematology·Terzah M HortonStephen P Hunger
Jul 26, 2011·Archivum Immunologiae Et Therapiae Experimentalis·Sanjay BatraMalaya K Sahoo
Dec 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William Bensinger
Jul 27, 2015·Toxics·Cristina Meregalli
Apr 14, 2005·Molecular Cancer Therapeutics·Dharminder ChauhanKenneth C Anderson
Sep 6, 2005·Cancer Research·Mikael AltunBenedikt M Kessler
Apr 1, 2006·The Lancet Oncology·Gareth J MorganFaith E Davies

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adhesion Molecules in Health and Disease

Cell adhesion molecules are a subset of cell adhesion proteins located on the cell surface involved in binding with other cells or with the extracellular matrix in the process called cell adhesion. In essence, cell adhesion molecules help cells stick to each other and to their surroundings. Cell adhesion is a crucial component in maintaining tissue structure and function. Discover the latest research on adhesion molecule and their role in health and disease here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.